RNS out4 Sep 2025 12:06
Oxford BioDynamics plc
("Oxford BioDynamics" or the "Company")
OBD's EpiSwitch CiRT Proven to Impact Clinical Treatment Decisions in Published Study
· Results strongly support CiRT's clinical utility in guiding immunotherapy decisions across a broad range of solid tumors
· CiRT test influenced real-world treatment choices in 61% of cases
· Company plans to apply for inclusion in US National Comprehensive Cancer Network clinical guidelines later this year
Oxford, UK - 04 September 2025 - Oxford BioDynamics Plc (AIM: OBD), a precision clinical diagnostics company bringing specific and sensitive tests to the practice of medicine based on its EpiSwitch® 3D genomics platform, announces the publication of interim results from its milestone FDA-registered PROWES trial (NCT06635954). The study, published in the high-impact medical journal Cancers1, demonstrates the clinical utility and treatment impact of its EpiSwitch CiRT (Checkpoint inhibitor Response Test).
The peer-reviewed publication of the ongoing PROWES prospective real-world study evaluated the clinical utility of OBD's CiRT blood test in guiding treatment decisions for 205 patients receiving immune checkpoint inhibitors (ICIs) across a broad range of advanced solid tumours. CiRT is a clinically validated blood test that predicts a cancer patient's likely response to ICIs, with high sensitivity (93%), specificity (82%) and accuracy (85%), across the most widely used ICIs2-3.
Thomas Guiel, COO of Oxford BioDynamics, said: "The PROWES results represent a significant milestone that further validates the transformative real-world impact of the EpiSwitch CiRT test on decision-making in real clinical practice.
"These results not only strengthen the scientific foundation of CiRT, but also support our strategy to secure inclusion in NCCN (National Comprehensive Cancer Network) clinical guidelines. The Company expects to apply for inclusion later this year, which is a critical step towards driving widespread adoption and achieving our commercial objectives."
The findings show that CiRT influenced oncologists' treatment choices in 61% of cases-including key decisions to initiate, escalate, de-escalate, or avoid therapy. Among patients with a Low Probability of Response CiRT result, nearly half avoided ineffective treatment, reducing unnecessary exposure to potentially serious or life-threatening toxicity. Conversely, almost three-quarters with a High Probability of Response had their treatment continued or escalated.
The study further demonstrated that CiRT results closely matched real-world patient outcomes and had broad applicability, remaining consistent across race, ethnicity, socioeconomic status, and whether treatment was in a major medical centre or community practice. Unlike existing invasive tissue-based tests, such as PD-L1 expression or genetic testing (TMB, MMR/MSI), often limited by poor predictive power, tumour type, a
Sign In
Follow the stocks
